5,6-二氢-4H-吡咯并[3,2,1-Ij]喹啉-2-羧酸 | 117273-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5,6-二氢-4H-吡咯并[3,2,1-Ij]喹啉-2-羧酸
• 英文名称: 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-2-carboxylic acid
• 英文别名: 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]chinolin-2-carbonsaeure；5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-2-carboxylic acid；1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraene-2-carboxylic acid
• CAS: 117273-45-7
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.225
• InChiKey: BFCHTANYIYJEKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6-二氢-4H-吡咯并[3,2,1-Ij]喹啉-2-羧酸 在 喹啉 、 copper oxide-chromium oxide 、 氢气 作用下， 生成 5,6-二氢-4H-吡咯并[3,2,1-ij]喹啉
  参考文献：
  名称：

  Synthesis of Polycyclic Indoles

  摘要：

  DOI：

  10.1021/ja01277a033
• 作为产物：
  描述：

  2-(3,4-dihydro-2H-[1]quinolylimino)-propionic acid 在 盐酸 作用下， 生成 5,6-二氢-4H-吡咯并[3,2,1-Ij]喹啉-2-羧酸
  参考文献：
  名称：

  Synthesis of Polycyclic Indoles

  摘要：

  DOI：

  10.1021/ja01277a033

文献信息

• Discovery of Tricyclic Indoles That Potently Inhibit Mcl-1 Using Fragment-Based Methods and Structure-Based Design
  作者：Jason P. Burke、Zhiguo Bian、Subrata Shaw、Bin Zhao、Craig M. Goodwin、Johannes Belmar、Carrie F. Browning、Dominico Vigil、Anders Friberg、DeMarco V. Camper、Olivia W. Rossanese、Taekyu Lee、Edward T. Olejniczak、Stephen W. Fesik

  DOI：10.1021/jm501984f

  日期：2015.5.14

  various chemotherapies. From an NMR-based screen of a large fragment library, several distinct chemical scaffolds that bind to Mcl-1 were discovered. Here, we describe the discovery of potent tricyclic 2-indole carboxylic acid inhibitors that exhibit single digit nanomolar binding affinity to Mcl-1 and greater than 1700-fold selectivity over Bcl-xL and greater than 100-fold selectivity over Bcl-2. X-ray

  髓样细胞白血病-1 (Mcl-1) 是 Bcl-2 蛋白家族的抗凋亡成员，在许多癌症中过度表达和扩增。 Mcl-1的过度表达使癌细胞能够逃避凋亡，并有助于癌细胞对各种化疗的有效治疗产生抵抗力。通过基于 NMR 的大片段库筛选，发现了几种与 Mcl-1 结合的不同化学支架。在这里，我们描述了有效的三环 2-吲哚羧酸抑制剂的发现，该抑制剂对 Mcl-1 表现出个位数纳摩尔的结合亲和力，选择性比 Bcl-xL 高 1700 倍，选择性比 Bcl-2 高 100 倍。这些化合物与 Mcl-1 复合时的 X 射线结构提供了有关这些小分子如何与靶标结合的详细信息，可用于指导化合物优化。
• HDAC Inhibitors
  申请人：Ashwell Mark A.

  公开号：US20100261710A1

  公开（公告）日：2010-10-14

  The present invention provides hydroxamic acid compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the hydroxamic acid compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention.

  本发明提供了羟肟酸化合物以及这些化合物的制备方法。本发明还涉及包含羟肟酸化合物的药物组合物。本发明提供了治疗细胞增殖性疾病（如癌症）的方法，通过向需要治疗的受试者施用本发明化合物的治疗有效剂量。
• 2-OXOINDOLINE DERIVATIVE
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP0731091A1

  公开（公告）日：1996-09-11

  Disclosed is a 2-oxoindoline derivative represented by the formula (I): (wherein Ring A represents a substituted or unsubstituted benzene ring, R1 represents H, a cycloalkyl group, an aryl group, a nitrogen-containing heterocyclic group, an oxygen-containing heterocyclic group, a sulfur-containing heterocyclic group, a heterocyclic group containing N and O, a heterocyclic group containing N and S, a lower alkoxy group, a carboxyl group, cyano group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, an oxiranyl group or a 2-(lower alkylthio)-1-hydroxyethyl group, R2 represents an aryl group, a group represented by the formula: a substituted or unsubstituted nitrogen-containing heteromonocyclic group, a substituted or unsubstituted nitrogen-containing heterobicyclic group, a group represented by the formula: (wherein n represents 1 or 2.), an oxygen-containing heterocyclic group, a sulfur-containing heterocyclic group, a heterocyclic group containing N and O or a heterocyclic group containing N and S, R3 represents a substituted or unsubstituted lower alkyl group, Q represents a single bonding arm or a lower alkylene group, Y represents a single bonding arm, a lower alkylene group or a lower alkenylene group.), and a pharmaceutically acceptable salt thereof.

  本发明公开了一种由式(I)代表的2-氧代吲哚啉衍生物： (其中环 A 代表取代或未取代的苯环，R1 代表 H、环烷基、芳基、含氮杂环基团、含氧杂环基团、含硫杂环基团、含 N 和 O 的杂环基团、含 N 和 S 的杂环基团、低级烷氧基、羧基、氰基、低级烷基硫基、低级烷氧基、羧基、氰基、低级烷基硫基）、一个含 N 和 S 的杂环基团、一个低级烷氧基基团、一个羧基基团、一个氰基基团、一个低级烷硫基基团、一个低级烷基亚磺酰基基团、一个低级烷基磺酰基基团、一个环氧乙烷基基团或一个 2-（低级烷硫基）-1-羟乙基基团： 一个取代或未取代的含氮杂单环基团、一个取代或未取代的含氮杂双环基团、一个由式......代表的基团： (其中 n 代表 1 或 2）、 含氧杂环基团、含硫杂环基团、含 N 和 O 的杂环基团或含 N 和 S 的杂环基团，R3 代表取代或未取代的低级烷基，Q 代表单键臂或低级亚烷基，Y 代表单键臂、低级亚烷基或低级亚烯基）、 及其药学上可接受的盐。
• [EN] HDAC INHIBITORS<br/>[FR] INHIBITEURS DES HDAC
  申请人：ARQULE INC

  公开号：WO2009026446A9

  公开（公告）日：2010-03-11
• Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718
  作者：Arie Van der Bent、Armand G. S. Blommaert、Caroline T. M. Melman、Adriaan P. IJzerman、Ineke Van Wijngaarden、Willem Soudijn

  DOI：10.1021/jm00084a009

  日期：1992.3

  A series of novel nonpeptide cholecystokinin-A (CCK-A) antagonists have been synthesized. Designed on the basis of the structural homology between lorglumide and L-364,718, as investigated with molecular modeling, these compounds constitute a link between the N-acylglutamic acid and 3-amino-5-phenyl-1,4-benzodiazepin-2-one derived antagonists. The prepared compounds were tested in vitro as antagonists of the binding of [H-3]-(+/-)-L-364,718 and [H-3]-CCK-8(S) to rat pancreas and guinea pig brain membranes, respectively. All compounds proved to be selective for the (peripheral) CCK-A receptor, the most potent analogue, 6, having a K(i) value of 90 nM. The structure-activity profile of the series of hybrid compounds relates closest to that of the N-acylglutamic acid derived antagonists.